Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896474818> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W2896474818 endingPage "e404" @default.
- W2896474818 startingPage "e404" @default.
- W2896474818 abstract "The American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) have developed frameworks to measure the clinical benefits of cancer therapies. We applied these frameworks to determine the clinical benefit of induction chemotherapy in locally advanced nasopharyngeal carcinoma treated with concurrent chemo-radiotherapy and to assess the associations between these two frameworks and between cost and each framework. We searched various biomedical databases for randomized trials (RCTs) comparing induction chemotherapy (IC) plus concurrent chemo-radiotherapy (CCRT) with CCRT alone in locally advanced nasopharyngeal carcinoma (LANPC). We scored the clinical benefit of IC using the ASCO version 2 (v2) framework, and ESMO Magnitude of Clinical Benefit Scale (MCBS) version 1.1 (v1.1). The total drug costs for IC were derived from 2017 average wholesale prices. Spearman correlation was used to assess the association between these two frameworks and between cost and each framework. We identified six eligible RCTs. The benefit of IC was scored ESMO-MCBS grade A in three RCTs and grade C in other three RCTs. The median ASCO net health benefit (NHB) is 5.5 (range -25 to 56). The median total costs of IC (USD) is 1344 (range 239 to 1911). There was strong correlation between ASCO and ESMO framework (spearman’s rho = 0.89, p value (P) = 0.02). There was positive correlation between total drug costs and ASCO NHB (spearman’s rho = 0.38, P = 0.46) and between total drug costs and ESMO-MCBS grade (spearman’s rho = 0.68, P = 0.13). The clinical benefit of adding IC in LANPC treated with CCRT was variable according to the ASCO and ESMO frameworks. There was a strong correlation between these two frameworks and positive correlations between framework outputs and drug costs." @default.
- W2896474818 created "2018-10-26" @default.
- W2896474818 creator A5026312862 @default.
- W2896474818 creator A5040456757 @default.
- W2896474818 creator A5065157802 @default.
- W2896474818 creator A5066056034 @default.
- W2896474818 creator A5091803557 @default.
- W2896474818 date "2018-11-01" @default.
- W2896474818 modified "2023-10-17" @default.
- W2896474818 title "Clinical Benefit of Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma Treated with Concurrent Chemoradiation Therapy According to ASCO and ESMO Frameworks." @default.
- W2896474818 doi "https://doi.org/10.1016/j.ijrobp.2018.07.1190" @default.
- W2896474818 hasPublicationYear "2018" @default.
- W2896474818 type Work @default.
- W2896474818 sameAs 2896474818 @default.
- W2896474818 citedByCount "0" @default.
- W2896474818 crossrefType "journal-article" @default.
- W2896474818 hasAuthorship W2896474818A5026312862 @default.
- W2896474818 hasAuthorship W2896474818A5040456757 @default.
- W2896474818 hasAuthorship W2896474818A5065157802 @default.
- W2896474818 hasAuthorship W2896474818A5066056034 @default.
- W2896474818 hasAuthorship W2896474818A5091803557 @default.
- W2896474818 hasBestOaLocation W28964748181 @default.
- W2896474818 hasConcept C121608353 @default.
- W2896474818 hasConcept C126322002 @default.
- W2896474818 hasConcept C143998085 @default.
- W2896474818 hasConcept C168563851 @default.
- W2896474818 hasConcept C2776598537 @default.
- W2896474818 hasConcept C2776611710 @default.
- W2896474818 hasConcept C2776694085 @default.
- W2896474818 hasConcept C2778997737 @default.
- W2896474818 hasConcept C509974204 @default.
- W2896474818 hasConcept C535046627 @default.
- W2896474818 hasConcept C71924100 @default.
- W2896474818 hasConceptScore W2896474818C121608353 @default.
- W2896474818 hasConceptScore W2896474818C126322002 @default.
- W2896474818 hasConceptScore W2896474818C143998085 @default.
- W2896474818 hasConceptScore W2896474818C168563851 @default.
- W2896474818 hasConceptScore W2896474818C2776598537 @default.
- W2896474818 hasConceptScore W2896474818C2776611710 @default.
- W2896474818 hasConceptScore W2896474818C2776694085 @default.
- W2896474818 hasConceptScore W2896474818C2778997737 @default.
- W2896474818 hasConceptScore W2896474818C509974204 @default.
- W2896474818 hasConceptScore W2896474818C535046627 @default.
- W2896474818 hasConceptScore W2896474818C71924100 @default.
- W2896474818 hasIssue "3" @default.
- W2896474818 hasLocation W28964748181 @default.
- W2896474818 hasOpenAccess W2896474818 @default.
- W2896474818 hasPrimaryLocation W28964748181 @default.
- W2896474818 hasRelatedWork W2085250315 @default.
- W2896474818 hasRelatedWork W2368018689 @default.
- W2896474818 hasRelatedWork W2371568951 @default.
- W2896474818 hasRelatedWork W2377959084 @default.
- W2896474818 hasRelatedWork W2385197461 @default.
- W2896474818 hasRelatedWork W2392262560 @default.
- W2896474818 hasRelatedWork W2894268253 @default.
- W2896474818 hasRelatedWork W2978265400 @default.
- W2896474818 hasRelatedWork W3030223433 @default.
- W2896474818 hasRelatedWork W3032139954 @default.
- W2896474818 hasVolume "102" @default.
- W2896474818 isParatext "false" @default.
- W2896474818 isRetracted "false" @default.
- W2896474818 magId "2896474818" @default.
- W2896474818 workType "article" @default.